<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Formoterol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Formoterol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Formoterol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11737" href="/d/html/11737.html" rel="external">see "Formoterol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13324" href="/d/html/13324.html" rel="external">see "Formoterol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F174082"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Perforomist</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866976"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Foradil [DSC];</li>
<li>Oxeze Turbuhaler</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F174122"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Beta<sub>2</sub> Agonist;</li>
<li>
                        Beta<sub>2</sub>-Adrenergic Agonist, Long-Acting</li></ul></div>
<div class="block doa drugH1Div" id="F174085"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ebd9659-c25b-4961-8c64-4b95099e6592">Asthma, maintenance/controller</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, maintenance/controller (adjunctive agent):</b>
<b> Note:</b> Use in combination with an inhaled corticosteroid and <b>not</b> as monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Foradil [Canadian product]: Dry powder inhaler (12 mcg/capsule): <b>Oral inhalation: </b>Contents of 1 capsule inhaled via Aerolizer device every 12 hours (maximum dose: 2 capsules/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oxeze Turbuhaler [Canadian product]: Dry powder inhaler (6 or 12 mcg/actuation): <b>Oral inhalation: </b>Initial: 6 or 12 mcg every 12 hours (maximum total daily dose: 24 mcg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c6f4720-28f3-4c2d-84c9-7afdfa8fd1a7">Chronic obstructive pulmonary disease, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic</b>
<b>obstructive pulmonary disease, maintenance:</b>
<b>Note:</b> Depending on symptoms and exacerbation risk, use monotherapy long-acting bronchodilator (long-acting beta agonist or long-acting muscarinic antagonist). In patients with more symptoms (eg, Group B), use in combination with long-acting muscarinic antagonist. In addition, a short-acting bronchodilator is used for intermittent symptom relief (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i> Perforomist: Nebulization solution: <b>Oral inhalation: </b>20 mcg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Foradil: Dry powder inhaler (12 mcg/capsule): <b>Oral inhalation:</b>
<b></b>Contents of 1 or 2 capsules inhaled every 12 hours using Aerolizer device (maximum dose: 4 capsules/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95c32f3a-f16a-445e-b218-18e8d3ce3500">Exercise-induced bronchospasm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exercise-induced bronchospasm:</b>
<b>Note:</b> May consider a combination ICS-formoterol for either an as-needed basis or for maintenance of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Oxeze Turbuhaler: Dry powder inhaler (6 or 12 mcg/actuation): <b>Oral inhalation: </b>6 mcg or 12 mcg at least 15 minutes before exercise on an occasional "as needed" basis (maximum dose: 48 mcg/24-hour period).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991879"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989207"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F174086"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F174105"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13324" href="/d/html/13324.html" rel="external">see "Formoterol: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing provided is for products available in Canada. The product available in the United States is not labeled for use in pediatric patients.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6eaf0529-96af-46d7-a15e-d8e3d1ed0ca2">Asthma, maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, maintenance therapy:</b>
<b>Note:</b> For asthma control, long-acting beta<sub>2</sub>-agonists (LABAs) should only be used in combination with inhaled corticosteroids; monotherapy is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Foradil [Canadian product]: Dry powder inhaler: 12 mcg/inhalation:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years and Adolescents ≤16 years: Oral inhalation: 12 mcg every 12 hours; maximum daily dose: 24 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥17 years: Oral inhalation: 12 mcg every 12 hours; in severe cases, 24 mcg every 12 hours may be necessary; maximum daily dose: 48 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Oxeze Turbuhaler [Canadian product]: Dry powder inhaler: 6 mcg/inhalation and 12 mcg/inhalation:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years and Adolescents ≤16 years: Oral inhalation: 6 mcg or 12 mcg every 12 hours; maximum daily dose: 24 mcg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥17 years: Oral inhalation: 6 mcg or 12 mcg every 12 hours; in severe cases, 24 mcg every 12 hours may be necessary; maximum daily dose: 48 mcg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea840e89-1dfd-4a61-bfa4-2dc7da759a32">Exercise-induced bronchospasm, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exercise-induced bronchospasm, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If already using formoterol in combination with inhaled corticosteroids for asthma maintenance, then patients should not use additional doses for exercise-induced bronchospasm. Because long-acting beta<sub>2</sub>-agonists (LABAs) may disguise poorly-controlled persistent asthma, frequent or chronic use of LABAs for exercise-induced bronchospasm is discouraged by asthma guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.2'])">Ref</a></span>). Tolerance to the protective effects of LABAs against exercise-induced bronchospasm may develop with regular use (ie, daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-GINA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling: </i>Oxeze Turbuhaler [Canadian product]: Dry powder inhaler: 6 mcg/inhalation and 12 mcg/inhalation:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents: Oral Inhalation: 6 mcg or 12 mcg before exercise on an occasional "as needed" basis; maximum daily dose: 24 mcg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51110582"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51110583"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F3413315"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Anxiety (2%), dizziness (2%), insomnia (2%), voice disorder (1%), headache</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2%), skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (5%), nausea (5%), xerostomia (1% to 3%), vomiting (2%), abdominal pain, dyspepsia, gastroenteritis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (2%), tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory tract infection (3% to 7%), exacerbation of asthma (ages 5 to 12 years: 5% to 6%; age &gt;12 years: &lt;4%; acute deterioration: &lt;1%), bronchitis (5%), pharyngitis (3% to 4%), sinusitis (3%), dyspnea (2%), tonsillitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Agitation, anaphylaxis (including severe hypotension/angioedema), angina pectoris, atrial fibrillation, behavioral changes, cardiac arrhythmia, cough, decreased glucose tolerance, dermatitis, disturbed sleep, dysgeusia, fatigue, hyperglycemia, hypertension, hypokalemia, malaise, metabolic acidosis, muscle spasm, nervousness, palpitations, paradoxical bronchospasm, prolonged QT interval on ECG, restlessness, tachycardia, urticaria, variable blood pressure, ventricular premature contractions</p></div>
<div class="block coi drugH1Div" id="F174065"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Monotherapy (without use of a concomitant inhaled corticosteroid) in the maintenance treatment of asthma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to formoterol or any component of the formulation; presence of tachyarrhythmias.</p></div>
<div class="block war drugH1Div" id="F174049"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma-related deaths: Use of long-acting beta-2 agonists (LABAs) as monotherapy (without inhaled corticosteroids) is associated with an increased risk of asthma-related death, asthma-related hospitalizations in pediatric and adolescent patients, and an increased risk of severe exacerbations (SMART 2006; Walters 2007). Data from large randomized, double-blind controlled trials do not show a significant increase in risk of serious asthma-related events (including hospitalizations, intubations, and death) in adults, adolescents, and pediatric patients when fixed-dose LABAs are used with inhaled corticosteroids combined in a single inhaler compared with inhaled corticosteroid monotherapy (FDA 2017). Current asthma guidelines recommend the use of an as-needed low dose inhaled corticosteroid with formoterol as the preferred reliever agent (GINA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Paradoxical bronchospasm (which can be life-threatening) may occur with use of inhaled agents; this reaction should be distinguished from inadequate response. Discontinue immediately if paradoxical bronchospasm occurs and institute alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serious effects/fatalities: Do not exceed recommended dose or frequency or use with other medications containing LABAs; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Appropriate use:</p>
<p style="text-indent:-2em;margin-left:6em;">- Foradil [Canadian product]: Not indicated for the initial (rescue) treatment of acute episodes of bronchospasm. Do <b>not</b> initiate in patients with significantly worsening or acutely deteriorating asthma; reports of severe (sometimes fatal) respiratory events have been reported when formoterol has been initiated in this situation.</p>
<p style="text-indent:-2em;margin-left:6em;">- Perforomist: Not FDA approved for the treatment of asthma; safety and efficacy in asthma patients have not been established with this product.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, or hypertension); beta-agonists may cause elevation in blood pressure and heart rate and result in CNS stimulation/excitation. Beta-2 agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic obstructive pulmonary disease: Appropriate use: Do <b>not</b> use for acute episodes of COPD. Do <b>not</b> initiate in patients with significantly worsening or acutely deteriorating COPD. Available data do not suggest an increased risk of death with use of LABAs in patients with COPD.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; beta-2 agonists may increase serum glucose and aggravate preexisting diabetes mellitus and ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Exercise-induced bronchospasm: Because LABAs may disguise poorly controlled persistent asthma, frequent or chronic use of LABAs for exercise-induced bronchospasm is discouraged (ATS [Parsons 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Use with caution in patients with hypokalemia; beta-2 agonists may transiently decrease serum potassium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Foradil [Canadian product]: LABAs, when used as monotherapy, may increase the risk of asthma-related hospitalization in pediatric and adolescent patients. When LABAs are used in a fixed-dose combination with inhaled corticosteroids, data from large clinical trials in adolescents do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to inhaled corticosteroids alone.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Foradil [Canadian product]: The contents of the capsules are for inhalation only via the Aerolizer device. There have been reports of incorrect administration (swallowing of the capsules).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Powder for oral inhalation may contain lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patient information: Patients using inhaled, short-acting beta-2 agonists should be instructed to discontinue routine use of these medications prior to beginning treatment; short-acting agents should still be provided to patients; however, use should be reserved for symptomatic relief of acute symptoms. Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use of short-acting beta-2 agonists may indicate deterioration of asthma or COPD, and medical evaluation must not be delayed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance/Tachyphylaxis: Tolerance to the bronchodilator effect, measured by FEV<sub>1</sub>, has been observed in studies.</p></div>
<div class="block prod-avail drugH1Div" id="F46720602"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Foradil Aerolizer is no longer available in the US.</p></div>
<div class="block foc drugH1Div" id="F174059"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation, as fumarate dihydrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Perforomist: 20 mcg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mcg/2 mL (2 mL)</p></div>
<div class="block geq drugH1Div" id="F174045"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F174067"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Nebulization</b> (Formoterol Fumarate Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mcg/2 mL (per mL): $4.07 - $10.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Nebulization</b> (Perforomist Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mcg/2 mL (per mL): $11.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866977"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxeze Turbuhaler: 6 mcg/actuation (51.4 g); 12 mcg/actuation (51.4 g) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Inhalation, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Foradil: 12 mcg [DSC] [contains milk protein]</p></div>
<div class="block adm drugH1Div" id="F174062"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Foradil [Canadian product]: Dry powder inhaler (capsule): For oral inhalation only (do not swallow capsules); administer at the same time each day. Remove capsule from blister pack <b>immediately</b> before use. Place capsule directly into capsule chamber of the Aerolizer inhaler; close inhaler and pierce capsule by pressing both blue side buttons simultaneously <b>once only</b> and then release. Exhale fully (do not exhale into inhaler) then close lips tightly around mouthpiece; inhale a deep breath through the mouthpiece; hold breath for as long as possible. If any powder remains in capsule, exhale and inhale again. Repeat until capsule is empty. Small pieces of gelatin may reach the mouth or throat after inhalation (minimized by not piercing capsule more than once); if this occurs, capsule is made of edible gelatin and is not harmful if ingested. Throw away empty capsule; do not leave in inhaler. If mouthpiece needs cleaning, wipe with a dry cloth or small soft brush.</p>
<p style="text-indent:-2em;margin-left:2em;">Oxeze Turbuhaler [Canadian product]: Dry powder inhaler: Hold inhaler upright. Turn colored grip as far as it will go in one direction and then turn back to original position; a clicking sound should be heard which means the inhaler is ready for use. Exhale fully. Do not exhale into mouthpiece of inhaler. Place mouthpiece to lips and inhale forcefully and deeply. Do not chew or bite on mouthpiece. Clean outside of mouthpiece once weekly with a dry tissue. Avoid getting inhaler wet. If the inhaler is accidently dropped or shaken, or if the patient exhales into the inhaler, the dose will be lost and a new dose should be loaded.</p>
<p style="text-indent:-2em;margin-left:2em;">Perforomist: Nebulization solution: Remove unit-dose vial from foil pouch <b>immediately</b> before use. Solution does not require dilution prior to administration; compatibility with other medications (eg, budesonide, revefenacin) in nebulizer has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20101066','lexi-content-ref-24172851','lexi-content-ref-32401744','lexi-content-ref-32324981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20101066','lexi-content-ref-24172851','lexi-content-ref-32401744','lexi-content-ref-32324981'])">Ref</a></span>); also refer to institution-specific policies. Place contents of unit-dose vial into the reservoir of a standard jet nebulizer connected to an air compressor; assemble nebulizer based on the manufacturer's instructions and turn nebulizer on; breathe deeply and evenly until all of the medication has been inhaled. The average inhalation time is 9 minutes. Discard any unused medication immediately; do not ingest contents of vial. Clean nebulizer after use.</p></div>
<div class="block admp drugH1Div" id="F52612885"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Foradil [Canadian product]: Dry powder inhaler: Remove capsule from blister pack <b>immediately</b> before use. The contents of a capsule are aerosolized via a device called an Aerolizer. Place the capsule into the capsule compartment in the base of the Aerolizer inhaler. Capsules must not be swallowed; must only use the Aerolizer Inhaler. Press both blue buttons <b>only</b>
<b>once</b> and then release. Keep inhaler in a level, horizontal position with the blue buttons to the left and right (not up and down) to avoid displacing powder. Exhale fully (with face pointed away from inhaler). Do not exhale into inhaler as this may dislodge powder. Tilt head slightly back and inhale (rapidly, steadily, and deeply). Hold breath as long as possible. If any powder remains in capsule, exhale and inhale again. Repeat until capsule is empty. Throw away empty capsule; do not leave in inhaler. Do not use a spacer with the Aerolizer Inhaler. Always keep capsules and inhaler dry.</p>
<p style="text-indent:-2em;margin-left:2em;">Oxeze Turbuhaler [Canadian product]: Dry powder inhaler: To prepare inhaler prior to use, load dose by holding inhaler in upright position and turn greenish-blue grip as far as it will go in one direction and then turn it as far as it will go in the other direction. Prior to first use, this procedure should be done twice; with subsequent dosing, perform this procedure once. Clicking sound means inhaler is loaded with dose and ready for use. Exhale fully. Do not exhale into mouthpiece of inhaler. Place mouthpiece between teeth and close lips over mouthpiece. Inhale deeply and forcefully. Do not chew or bite on mouthpiece. Do not exhale through inhaler. If the Turbuhaler is dropped, shaken, or breathed into after it is loaded, the dose will be lost and a new dose will need to be loaded. Clean outside of mouthpiece once weekly with a dry tissue. Avoid getting inhaler wet. Discard device after a 0 displays in the dose window.</p></div>
<div class="block use drugH1Div" id="F174060"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic obstructive pulmonary disease, maintenance:</b> Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Asthma:</b> Treatment of asthma (only in combination with an inhaled corticosteroid) in ≥6 years of age and adult patients with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma (Foradil, Oxeze Turbuhaler).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic obstructive pulmonary disease, maintenance:</b> Maintenance treatment of COPD (Foradil).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Exercise-induced bronchospasm:</b> Prevention of exercise-induced bronchospasm when administered on an as-needed basis (monotherapy may be indicated in patients without persistent asthma) in ≥6 years of age and adult patients (Oxeze Turbuhaler).</p></div>
<div class="block mst drugH1Div" id="F174129"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Foradil [CAN] may be confused with Toradol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Foradil capsules for inhalation are for administration via Aerolizer inhaler and are <b>not</b> for oral use.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Foradil [Canada and multiple international markets] may be confused with Fortical brand name for calcium carbonate [LB] and Theradol brand name for tramadol [Netherlands]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F174116"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F174053"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists (Long-Acting): May enhance the adverse/toxic effect of other Beta2-Agonists (Long-Acting).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: May enhance the adverse/toxic effect of Formoterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Formoterol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta2-Agonists (Long-Acting) may diminish the therapeutic effect of Methacholine.  Management: Hold long-acting beta<sub>2</sub> agonists for 36 hours before methacholine use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta2-Agonists may enhance the adverse/toxic effect of Theophylline Derivatives. Specifically, sympathomimetic effects may be increased. Theophylline Derivatives may enhance the hypokalemic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F174068"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Maternal use of beta-2 agonists are not associated with an increased risk of fetal malformations (GINA 2023). Uncontrolled asthma is associated with adverse events in pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes) (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Formoterol may be used when a long-acting beta-2 agonist (LABA) is needed for the management of asthma in pregnancy. Patients adequately controlled on formoterol for asthma may continue therapy; if initiating treatment during pregnancy, use of a LABA with more data in pregnant patients may be preferred (ERS/TSANZ [Middleton 2020]). Stepping down controller treatment is not recommended during pregnancy (GINA 2023). Maternal asthma symptoms should be monitored monthly (ERS/TSANZ [Middleton 2020], GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Beta agonists may interfere with uterine contractility if administered during labor.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes associated with asthma and the medications used to treat asthma in pregnancy is ongoing. Health care providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (877-311-8972 or https://mothertobaby.org). Patients may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F20472459"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if formoterol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Formoterol oral inhalation is considered probably acceptable for use while breastfeeding (ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block mop drugH1Div" id="F174057"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; shortness of breath; blood pressure, heart rate; CNS stimulation; serum glucose, serum potassium</p></div>
<div class="block pha drugH1Div" id="F174048"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Relaxes bronchial smooth muscle by selective action on beta<sub>2</sub> receptors with little effect on heart rate. Formoterol has a long-acting effect.</p></div>
<div class="block phk drugH1Div" id="F174064"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Dry powder inhaler: Within 3 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Dry powder inhaler: 80% of peak effect within 15 minutes; Nebulization solution: 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Improvement in FEV<sub>1</sub> observed for 12 hours in most patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapidly into plasma.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 61% to 64% <i>in vitro</i> at higher concentrations than achieved with usual dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via direct glucuronidation and O-demethylation; CYP2D6, CYP2C8/9, CYP2C19, CYP2A6 involved in O-demethylation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Dry powder inhaler: ~10 to 14 hours; Nebulization solution: ~7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Maximum improvement in FEV<sub>1</sub> in 1 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 5 to 12 years: Urine (7% to 9% as direct glucuronide metabolites, 6% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Urine (15% to 18% as direct glucuronide metabolites, 2% to 10% as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F174069"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fordilen | Formovent | Xanol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Foradil | Forair | Formoterol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Foradile</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Foradil | Formagal | Formoair</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fluir | Foradil | Formare | Formocaps</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Foradil HFA</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Raforex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fordilen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Fesema | Foradil | Sinasfix</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Formano | Formomyl | Formoterol | Formoterol ratiopharm | Formovent | Forotel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Cyclocaps Formoterol | Foradil | Foradil certihaler | Foradil P | Forair | Formo | Formoair | Formolich | Formoterol al | Formoterol CT | Formoterol ratiopharm | Formoterol Sandoz</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Etiterol | Foradil | Fortel | Fortel inhalador</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Galiron</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alveobreeze | Atimos | Foradil | Foratec</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Broncoral | Broncoral neo | Foradil | Formoterol aldo union | Formoterol bayvit</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cycloterol | Foradil | Formaxa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Formoair | Formoterol biogaran | Formoterol eg | Formoterol mylan | Formoterol zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Edufil | Foradil | Forair | Forcap | Formaxa | Imotec</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Forair | Inhafort | Reviform</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Deriform | Foratec</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aliterol | Atimos | Eolus | Evervent | Feronal | Foradil | Formoterolo eg | Forotan | Kurovent | Levovent | Liferol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Foradil | Foratec | Formagal</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Foradil | Foratec hfa</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Forair | Galiron</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Foradil | Formagal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Broncotec | Foradil | Formoterol smb</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Foradil | Icarus</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Formoterol | Formoterol a | Formoterolfumaraatdihydraat bmodesto</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Atimos</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Foramed | Forastmin | Oxodil Pph | Zafiron</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Foradil | Perforomist</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Asmatec | Atimos | Broncotec | Foradil | Formoterol | Formoterol mylan | Formoterol Teva</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Foradil | Foterol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Formoterol | Formoterol air | Formoterol nativ | Formoterol psk</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Atimos</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Formano | Formostad | Formoterol | Formoterol cipla | Formoterol Sandoz | Formovent</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aerofor | Atimos | Foradil | Notos easy flow | Raforex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Atimos | Foradil | Foterol | Ventofor</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fortix</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Foradil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fenorol | Fluir | Foradil | Formotec</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Foradil | Foratec | Foratec hfa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20101066">
<a name="20101066"></a>Burchett DK, Darko W, Zahra J, Noviasky J, Probst L, Smith A. Mixing and compatibility guide for commonly used aerosolized medications. <i>Am J Health Syst Pharm</i>. 2010;67(3):227-230. doi:10.2146/ajhp080261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/20101066/pubmed" id="20101066" target="_blank">20101066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11162418">
<a name="11162418"></a>Cazzola M, Centanni S, Regorda C, et al, “Onset of Action of Single Doses of Formoterol Administered Via Turbuhaler in Patients With Stable COPD,” <i>Pulm Pharmacol Ther</i>, 2001, 14:41-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/11162418/pubmed" id="11162418" target="_blank">11162418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10983735">
<a name="10983735"></a>Cazzola M and Donner CF, “Long-Acting Beta<sub>2</sub>-Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease,” <i>Drugs</i>, 2000, 60:307-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/10983735/pubmed" id="10983735" target="_blank">10983735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.1">
<a name="Novartis.1"></a>Foradil Bronchodilator (formoterol) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Updated 2020. Accessed May 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2">
<a name="GINA.2"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/wp-content/uploads/2023/01/GOLD-2023-ver-1.2-7Jan2023_WMV.pdf. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24172851">
<a name="24172851"></a>Kamin W, Erdnüss F, Krämer I. Inhalation solutions—which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers—update 2013. <i>J Cyst Fibros</i>. 2014;13(3):243‐250. doi:10.1016/j.jcf.2013.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/24172851/pubmed" id="24172851" target="_blank">24172851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>National Asthma Education and Prevention Program (NAEPP). Asthma management guidelines: focused updates 2020. Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 20-HL-8140.<a href="https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates" target="_blank">https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates</a> Published December 2020. Accessed January 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.2">
<a name="NAEPP.2"></a>National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href="https://www.nhlbi.nih.gov/sites/default/files/media/docs/EPR-3_Asthma_Full_Report_2007.pdf" target="_blank">https://www.nhlbi.nih.gov/sites/default/files/media/docs/EPR-3_Asthma_Full_Report_2007.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16424409">
<a name="16424409"></a>Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. <i>Chest</i>. 2006;129(1):15-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/16424409/pubmed" id="16424409" target="_blank">16424409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32401744">
<a name="32401744"></a>Ngim K, Patel J. Physicochemical stability and compatibility of revefenacin (LAMA) and formoterol fumarate (LABA) inhalation solution admixture.<i> Int J Pharm Compd</i>. 2020;24(3):242-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/32401744/pubmed" id="32401744" target="_blank">32401744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AstraZenecaCanada.1">
<a name="AstraZenecaCanada.1"></a>Oxeze Turbuhaler (formoterol) [product monograph]. Mississauga, Ontario, Canada: AstraZenecaCanada Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23634861">
<a name="23634861"></a>Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. <i>Am J Respir Crit Care Med</i>. 2013;187(9):1016‐1027. doi:10.1164/rccm.201303-0437ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/23634861/pubmed" id="23634861" target="_blank">23634861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Perforomist (formoterol) [prescribing information]. Morgantown, WV: Mylan Specialty L.P; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2844878">
<a name="2844878"></a>Scarpace PJ. Decreased receptor activation with age. Can it be explained by desensitization? <i>J Am Geriatr Soc</i>. 1988;36(11):1067-1071.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/2844878/pubmed" id="2844878" target="_blank">2844878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32324981">
<a name="32324981"></a>Siler TM, Moran EJ, Barnes CN, Crater GD. Safety and efficacy of revefenacin and formoterol in sequence and combination via a standard jet nebulizer in patients with chronic obstructive pulmonary disease: a phase 3b, randomized, 42-day study. <i>Chronic Obstr Pulm Dis</i>. 2020;7(2):99-106. doi:10.15326/jcopdf.7.2.2019.0154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/32324981/pubmed" id="32324981" target="_blank">32324981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. <a href="http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Published August 28, 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration. FDA drug safety communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes</a>. Published December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17253458">
<a name="17253458"></a>Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. <i>Cochrane Database Syst Rev</i>. 2007;(1):CD001385. doi:10.1002/14651858.CD001385.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/17253458/pubmed" id="17253458" target="_blank">17253458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27665489">
<a name="27665489"></a>Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update-2016. <i>J Allergy Clin Immunol</i>. 2016;138(5):1292-1295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/formoterol-drug-information/abstract-text/27665489/pubmed" id="27665489" target="_blank">27665489</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8946 Version 313.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
